MediWound Ltd.
$17.35
▲
3.77%
2026-04-21 08:06:00
www.mediwound.com
NGM: MDWD
Explore MediWound Ltd. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$226.34 M
Current Price
$17.35
52W High / Low
$22.5 / $14.9
Stock P/E
—
Book Value
$3.4
Dividend Yield
—
ROCE
-41.75%
ROE
-63.86%
Face Value
—
EPS
$-2.1
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
121
Beta
0.15
Debt / Equity
20.11
Current Ratio
2.33
Quick Ratio
2.17
Forward P/E
-8.23
Price / Sales
13.53
Enterprise Value
$184.93 M
EV / EBITDA
-7.62
EV / Revenue
10.9
Rating
Strong Buy
Target Price
$31.33
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | X4 Pharmaceuticals, Inc. | $4.19 | — | $372.04 M | — | -32.82% | -75.99% | $6.63 / $1.35 | $2.05 |
| 2. | Sagimet Biosciences Inc. | $6.44 | — | $206.19 M | — | -51.08% | -38.2% | $11.41 / $2.02 | $3.42 |
| 3. | MAIA Biotechnology, Inc. | $1.41 | — | $81.91 M | — | -618.06% | -7.45% | $3.19 / $0.87 | $0.06 |
| 4. | SciSparc Ltd. | $4.23 | — | $2.5 M | — | -80.93% | -12.81% | $94.5 / $2.98 | $142.32 |
| 5. | Decoy Therapeutics Inc. | $5.89 | — | $3.09 M | — | -379.33% | -3.38% | $415.8 / $5.4 | $11.07 |
| 6. | XBiotech Inc. | $2.51 | — | $78.32 M | — | -39.17% | -28.23% | $3.61 / $2.09 | $4.6 |
| 7. | IGC Pharma, Inc. | $0.32 | — | $31.52 M | — | -114.73% | -83.34% | $0.5 / $0.24 | $0.09 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 1.87 M | 5.43 M | 5.71 M | 3.96 M | 5.84 M | — |
| Operating Profit | -7.81 M | -6.53 M | -5.72 M | -5.22 M | -6.08 M | — |
| Net Profit | -7.18 M | -2.65 M | -13.32 M | -0.73 M | -3.91 M | — |
| EPS in Rs | -0.56 | -0.21 | -1.04 | -0.06 | -0.3 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 16.96 M | 20.22 M | 18.69 M | 26.5 M |
| Operating Profit | -25.28 M | -19.38 M | -15.5 M | -7.66 M |
| Net Profit | -23.88 M | -30.22 M | -6.72 M | -19.6 M |
| EPS in Rs | -1.86 | -2.35 | -0.52 | -1.52 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 86.25 M | 73.5 M | 66.46 M | 50.02 M |
| Total Liabilities | 42.62 M | 42.34 M | 34.86 M | 39.1 M |
| Equity | 43.63 M | 31.15 M | 31.59 M | 10.91 M |
| Current Assets | 59.96 M | 52.16 M | 49.7 M | 45.84 M |
| Current Liabilities | 25.71 M | 26.54 M | 18.12 M | 12.06 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -16.12 M | -13.62 M | -10.46 M | -11.88 M |
| Investing CF | -17.95 M | -8.4 M | -34.32 M | -0.48 M |
| Financing CF | 29.62 M | 19.39 M | 22.92 M | 35.76 M |
| Free CF | -21.63 M | -19.9 M | -16.93 M | -12.44 M |
| Capex | -5.5 M | -6.27 M | -6.46 M | -0.56 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 8.22% | -29.48% | — | — |
| Earnings Growth % | -350.03% | 65.73% | — | — |
| Profit Margin % | -149.46% | -35.94% | -73.97% | — |
| Operating Margin % | -95.85% | -82.96% | -28.91% | — |
| Gross Margin % | 13.03% | 19.15% | 49.69% | — |
| EBITDA Margin % | -138.11% | -25.69% | -68.87% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2022-12-20 | 1:0.142857 |